Biotechnology

Arima Genomics' award-winning Aventa test is revolutionizing lymphoma diagnostics by seeing cancer in 3D, moving beyond 2D methods to find what others miss.

Adial Pharmaceuticals pivots from addiction to inflammation, securing $32M and poaching Azora's leadership to drive its new ulcerative colitis drug, AT177.

Eli Lilly's Zepbound secures a landmark approval for sleep apnea, moving beyond weight loss to redefine chronic disease management and challenge competitors.

LRM Aesthetics' new delivery system for its PDGF+ formula isn't just a product update; it’s a masterclass in how small innovations create major workflow gains.

A biotech firm's non-hallucinogenic drug just passed a key safety test. Could this novel approach finally disrupt the challenging world of alcohol use disorder?

Acumen Pharmaceuticals unveils two new candidates using a novel technology to deliver therapies directly to the brain, promising a more effective fight against AD.

A new patent gives Cognition Therapeutics’ lead drug candidate protection until 2045. Here’s why this strategic move is about more than just IP.

Pluristyx secures a key Japanese patent for its rapid mRNA reprogramming tech, slashing iPSC production time and promising to unlock commercial-scale cell therapy.

A new pact between Canada’s CASTL and Ireland’s NIBRT, backed by top leaders, aims to solve a critical talent shortage and secure the global pharma supply chain.

A new surgical method called SMART, developed at Delray Medical Center, uses biological scaffolds to overcome the failure of sutures in critical muscle injuries.

The 8th annual 'Shine the Light' campaign unites 47 groups to fight Sickle Cell Disease, but behind the red-lit landmarks lies a deeper crisis of access to new, multi-million dollar cures.

Pharma giant MSD and health-tech innovator Nivi are using an AI chatbot to fight cervical cancer in Asia. Can this model overcome regulatory hurdles and scale?

A new partnership between Matica Bio and Cirsium Biosciences aims to shatter the high-cost, closed-off world of gene therapy manufacturing. Is this the key?

Tiny biotech HCW Biologics reports promising early data for its alopecia drug. But with a small sample size and big pharma rivals, is this a true breakthrough?

As Latus Bio advances its Huntington's therapy to clinic, new CBO Bethany Mancilla brings a history of high-value deals to fuel the company's growth.

The company behind the first FDA-cleared birth control app is expanding into a holistic wellness platform, a strategic move that could redefine the FemTech market.

Verge Labs' new AI model promises to predict brain activity from a blood draw, potentially upending the costly and failure-prone world of neurology R&D.

The appointment of drug development veteran Dr. Aaron Koenig at Syremis Therapeutics is more than a new hire; it's a strategic play in the high-stakes race to redefine mental health treatment.

Pasithea Therapeutics is expanding its NF1 trial for PAS-004, a move that signals a deeper strategic commitment to outmaneuvering competitors and meeting a critical unmet medical need.

German firm NVision wins a top award for POLARIS, a quantum-enhanced MRI platform that shows if cancer therapy is working weeks or months sooner.